Key Catalyst In August For Mologen As IMPALA Phase III Colorectal Cancer Reports

 
• By Sten Stovall
  
DNA strand
Mologen's immunotherapy focus is on developing DNA-based TLR9 agonists • Source: Shutterstock

More from Clinical Trials

More from R&D